Similar articles

• Virtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibe administration: HEAVEN study.

  Kovarnik T, Mintz GS, Skalicka H, Kral A, Horak J, Skulec R, Uhrova J, Martasek P, Downe RW, Wahle A, Sonka M, Mrazek V, Aschermann M, Linhart A. Kovarnik T, et al. Circ J. 2012;76(1):176-83. doi: 10.1253/circj.cj-11-0730. Epub 2011 Nov 10. Circ J. 2012. PMID: 22076422 Clinical Trial.
• Atorvastatin reduces coronary plaque volume in dependence on reductions in low-density lipoprotein: a meta-analysis and meta-regression of randomized controlled trials.

  Takagi H, Umemoto T. Takagi H, et al. Int J Cardiol. 2012 May 17;157(1):114-6. doi: 10.1016/j.ijcard.2012.01.078. Epub 2012 Feb 14. Int J Cardiol. 2012. PMID: 22341753 No abstract available.
• Rationale and design of a randomized clinical study to investigate the effect of ezetimibe, a cholesterol absorption inhibitor, on the regression of intracoronary plaque evaluated by non-obstructive angioscopy and ultrasound: The ZIPANGU study.

  Hiro T, Hirayama A, Ueda Y, Komatsu S, Matsuoka H, Takayama T, Ishihara M, Hayashi T, Saito S, Kodama K; ZIPANGU investigators. Hiro T, et al. J Cardiol. 2014 Dec;64(6):501-7. doi: 10.1016/j.jjcc.2014.02.026. Epub 2014 Apr 13. J Cardiol. 2014. PMID: 24725763 Clinical Trial.
• Pitavastatin: novel effects on lipid parameters.

  Chapman MJ. Chapman MJ. Atheroscler Suppl. 2011 Nov;12(3):277-84. doi: 10.1016/S1567-5688(11)70887-X. Atheroscler Suppl. 2011. PMID: 22152282 Review.
• Evaluating the safety of Liptruzet (ezetimibe and atorvastatin): what are the potential benefits beyond low-density lipoprotein cholesterol-lowering effect?

  Husain NE, Hassan AT, Elmadhoun WM, Ahmed MH. Husain NE, et al. Expert Opin Drug Saf. 2015;14(9):1445-55. doi: 10.1517/14740338.2015.1063613. Epub 2015 Jul 3. Expert Opin Drug Saf. 2015. PMID: 26134926 Review.